Dermatology

Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.

Experts discuss the use of biologics in the treatment of rare dermatologic disorders.

In this interview, Marinkovich discussed the implications of the FDA’s landmark approval of B-VEC topical gene therapy for patients with the “butterfly disease.”

In this interview, Stucky discussed his team’s research into an uptick in oral minoxidil prescribing rates for hair loss that had immediately followed the publication of a New York Times article.

During this interview segment, Friedman further explored the topics in his presentation on fixing disparities in care for eczema patients through teledermatology.

Dermatology experts review available treatment options for the treatment of rare dermatological disorders.

Experts discuss challenges in managing rare dermatological disorders.

In this interview, Hebert discussed recent positive topline results from the ADORING 1 trial on tapinarof cream for atopic dermatitis patients aged 2 years and older.

The Food and Drug Administration approved the intradermal microdroplet injection, a hydrating gel product designed to smooth out patients’ skin in those over 21 of all Fitzpatrick skin types.

Experts discuss what types of skin symptoms prompt patients to go to the emergency room.

Dermatology experts discuss why it is important to recognize dermatologic conditions correctly and how a misdiagnosis and delay of treatment can cause irreversible and unnecessary harm.

A research letter highlighted coverage in The New York Times of a small study on oral minoxidil and this story’s connection with an immediate increase in the drug’s prescription rates.

New data indicate that once-daily roflumilast foam in treating seborrheic dermatitis may improve the lives of those in the 5% or more of the global population with the skin disease.

Experts discuss the typical journey of a patient with rare dermatologic conditions.

Benjamin Kaffenberger, MD, discusses the underlying pathophysiology of GPP, PPP, and SJS.

Investigators found that dermatologist and convolutional neural network-cooperation led to improved lesion classification, indicating potential benefits of the human and machine approach for patients.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.

Some agents with unique mechanisms of action are nearing late-stage research for the treatment of eczema.

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.

David Rosmarin, MD, reviews a quintet of promising agents advancing in late stages while at RAD 2023.

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.